Fatima Ayesha, Fernyhough Liam Joseph, Mohammed Abdul Moqeeth, Haider Vajeeha, Eltahir Asma
Family Medicine, Primary Health Care Corporation, Doha, QAT.
Hematology and Medical Oncology, Weil Cornell Medical College, Doha, QAT.
Cureus. 2024 Oct 1;16(10):e70627. doi: 10.7759/cureus.70627. eCollection 2024 Oct.
Clomiphene citrate is a selective estrogen receptor modulator commonly used off-label for male infertility despite being approved only for female infertility. Clomiphene is generally safe, and serious adverse effects such as venous thrombosis are rarely reported. This report presents the case of a 32-year-old man who developed portal vein thrombosis (PVT) and superior mesenteric venous thrombosis (SMVT) following three months of clomiphene therapy for infertility. The patient presented with severe abdominal pain and was found to have acute thrombosis on CT imaging. No other underlying hypercoagulable condition was present, and clomiphene was identified as a possible provoking factor for the thrombosis. The patient was successfully treated with anticoagulation therapy and was discharged on dabigatran for six months, with follow-up imaging planned. This is the first reported case linking clomiphene use to PVT and SMVT. Further studies are necessary to better understand the degree of risk and mechanisms underlying clomiphene-induced thrombosis.
枸橼酸氯米芬是一种选择性雌激素受体调节剂，尽管仅被批准用于治疗女性不孕症，但常用于男性不孕症的非标签治疗。氯米芬总体上是安全的，很少有静脉血栓形成等严重不良反应的报告。本报告介绍了一名32岁男性的病例，该男性在接受氯米芬治疗不孕症三个月后发生了门静脉血栓形成（PVT）和肠系膜上静脉血栓形成（SMVT）。患者出现严重腹痛，CT成像发现急性血栓形成。未发现其他潜在的高凝状态，氯米芬被确定为血栓形成的可能诱发因素。患者接受抗凝治疗成功，出院时服用达比加群六个月，并计划进行随访成像。这是首例报道的将氯米芬使用与PVT和SMVT相关联的病例。有必要进行进一步研究，以更好地了解氯米芬诱导血栓形成的风险程度和潜在机制。
